Related Experiment Video
Updated: May 23, 2026
07:15
Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
Clarithromycin-Induced Long QT Syndrome: A Case Report
Mecnun Cetin1, Munevver Yıldırımer, Serkan Ozen
1Division of Pediatric Cardiology, Department of Pediatrics, Faculty of Medicine, Celal Bayar University, 45010 Manisa, Turkey.
Case Reports in Medicine
|April 11, 2012
Summary
Clarithromycin, an antibiotic for atypical pneumonia, can cause Long QT syndrome. This condition involves dangerous heart rhythm changes, highlighting the need for careful drug monitoring.
Area of Science:
- Cardiology
- Pharmacology
- Infectious Diseases
Background:
- Long QT syndrome (LQTS) is a cardiac disorder associated with increased risk of arrhythmias.
- Non-antiarrhythmic drug-induced QT interval prolongation is a growing concern in clinical practice.
- Clarithromycin, a macrolide antibiotic, is widely prescribed for atypical pneumonia.
Observation:
- A case of a patient treated with clarithromycin for atypical pneumonia is presented.
- The patient developed significant QT interval prolongation after initiating clarithromycin therapy.
Findings:
- Clarithromycin administration was temporally associated with the onset of Long QT syndrome in this patient.
- This case underscores the potential cardiotoxic effects of clarithromycin.
Implications:
- Clinicians should be vigilant for potential cardiac side effects of clarithromycin.
- Further research into drug-induced LQTS is warranted to ensure patient safety.
- Consideration of alternative antibiotics may be necessary in patients with risk factors for QT prolongation.
Related Concept Videos
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:15Pharmacodynamic Models: Linear Concentration–Effect Model
The linear concentration–effect model, underpinned by the principle that pharmacological effect (E) is directly proportional to plasma drug concentration (C), emerges as a pivotal simplification of the Emax model for conditions where C is significantly less than EC50. This model portrays a linear trajectory of the concentration–effect relationship when drug levels are markedly below the EC50 threshold.Despite its inherent assumption of continuous effect augmentation with increasing drug...
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
01:27Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...